Regeneron Pharmaceuticals has entered a major strategic collaboration with TriNetX, investing up to $200 million. Announced on April 2, 2026, the deal gives Regeneron exclusive access to de-identified electronic health records (EHRs) from approximately 300 million patients (including 170 million in the US) in TriNetX’s global network. This will enable large scale linking of Regeneron’s genomic and proteomic data with real world clinical phenotypes to accelerate drug discovery and development.
Glimpse:
The partnership integrates Regeneron Genetics Center’s (RGC) data which has sequenced over 2 million exomes and genomes with TriNetX’s rich longitudinal phenotypic data using privacy preserving methods like federated querying. The expanded database will support novel target identification, better clinical trial design with real world evidence, precision medicine, and future digital health innovations while maintaining strict HIPAA and GDPR compliance.
Regeneron Pharmaceuticals and TriNetX, a leading global health research network, have announced a significant collaboration that strengthens Regeneron’s capabilities in genetics driven drug discovery and development. As part of the agreement, Regeneron will invest up to $200 million in TriNetX and gain exclusive rights to connect its large-scale genomic and proteomic datasets with TriNetX’s extensive de-identified electronic health record network.
TriNetX provides access to anonymized longitudinal data from nearly 300 million patients worldwide, including 170 million individuals in the United States. This data comes from thousands of health systems and academic medical centres. Using advanced privacy preserving technologies such as federated querying and secure data matching, Regeneron will be able to link its Regeneron Genetics Center (RGC) multi-omic insights derived from over 2 million sequenced exomes and genomes with real world clinical phenotypes at an unprecedented scale
The combined dataset is expected to accelerate multiple critical areas: identifying novel therapeutic targets through population scale analysis, optimising clinical trial recruitment and design with robust real world evidence, advancing precision medicine, and supporting new digital health solutions for patients and providers. The collaboration also opens opportunities for developing AI-driven predictive models and analysing broad health trends while fully complying with global privacy regulations like HIPAA and GDPR.
TriNetX will continue serving other life sciences organisations through its open platform, while Regeneron receives exclusive rights to these unique data linkages. The partnership is viewed as a major step in leveraging real-world data to drive more efficient and targeted drug development in the life sciences industry.
“We are delighted to work with Regeneron, and specifically the Regeneron Genetics Center team, to advance human health through the application of intelligence driven information technology, powered by our trusted data. Our team is gratified to be selected by Regeneron to provide access to TriNetX’s unique breadth and depth of research-ready data, across our extensive federated global network of academic medical centres and other leading healthcare research sites.”
By
HB Team
Related News
